PIONEERS IN CELL THERAPY

Chimeric Therapeutics is a results-driven cancer cell therapy company with 3 CAR T & NK cell assets all in Phase 1/1b clinical trials.

our PORTFOLIO

First in class

Chimeric Therapeutic's diversified portfolio includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. These assets are being developed across multiple different disease areas in oncology.

CDH17

A first in CAR-T Therapy, CDH17 CAR T was invented at Penn's world-renowned cell therapy centre, and is currently being studied in a phase 1/2 clinical trial.

CLTX

'The Scorpion Killer', CLTX is a novel and promising CAR T therapy that is unique in its use of Chlorotoxin, a peptide derived from deathstalker scorpion venom.

CORE NK

With two phase 1b trials initiated, CORE-NK is a potentially best-in-class, clinically-validated NK cell platform for our next generation of assets.

ABOUT US

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

WHY CHIMERIC?

Targeting more

Traditional cancer drug development focuses on delaying disease progression We believe that novel cell therapies have the promise to do more. Chimeric’s world class team of cell therapy pioneers and experts is working towards a world where all patients with advanced cancer receive transformative therapies.